dual agonist glp 1 The glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor tirzepatide: a novel cardiometabolic therapeutic prospect | Cardiovascular Diabetology Curious about the latest in
Description
(2025) explores current evidence, challenges, and future perspectives in managing surgical patients on GLP-1R agonists
The airball comes as Novo scrambles to regain a majority share of the GLP-1 market.
Discover the research, how they work, who should try these, and more.
Both glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter-2 (SGLT-2) inhibitors can reduce CV risk in patients with T2D, and both are recommended by the American Diabetes Association to reduce the risk of major cardiovascular events (MACE)
Thirteen state Medicaid programs are covering GLP-1 drugs for the treatment of obesity this year, down from 16 last year.
If you are taking medications or have a medical condition, speak with your provider before use
